Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.

ABSTRACT:

SUBMITTER: Madhi SA 

PROVIDER: S-EPMC9045746 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature